• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国对 Takayasu 动脉炎治疗的建议。

French recommendations for the management of Takayasu's arteritis.

机构信息

Internal medicine, Pitié Salpêtrière Hospital, Paris, France.

Vascular medicine, CHU Toulouse, Toulouse, France.

出版信息

Orphanet J Rare Dis. 2021 Jul 21;16(Suppl 3):311. doi: 10.1186/s13023-021-01922-1.

DOI:10.1186/s13023-021-01922-1
PMID:34284801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8293493/
Abstract

The aim of this National Diagnostic and Care Protocol (PNDS) is to explain to the professionals involved the current optimal diagnosis and therapeutic management and care approach for a patient with Takayasu's arteritis. Its purpose is to optimize and harmonize the management and follow-up of this rare disease throughout the country. It also identifies pharmaceutical specialties used in an indication not provided for in the Marketing Authorization, as well as the specialties, products or services necessary for the care of patients but not usually paid for or reimbursed.

摘要

本国家诊断和护理方案(PNDS)的目的是向相关专业人员解释目前针对 Takayasu 动脉炎患者的最佳诊断和治疗管理及护理方法。其目的是优化和协调全国范围内对这种罕见疾病的管理和随访。它还确定了在药品许可未涵盖的适应症中使用的药品专业知识,以及患者护理所需的专业知识、产品或服务,但通常不支付或报销。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/1d60f45b52c4/13023_2021_1922_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/e517064bea9a/13023_2021_1922_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/47da2a46885e/13023_2021_1922_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/1d60f45b52c4/13023_2021_1922_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/e517064bea9a/13023_2021_1922_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/47da2a46885e/13023_2021_1922_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff8/8293493/1d60f45b52c4/13023_2021_1922_Fig3_HTML.jpg

相似文献

1
French recommendations for the management of Takayasu's arteritis.法国对 Takayasu 动脉炎治疗的建议。
Orphanet J Rare Dis. 2021 Jul 21;16(Suppl 3):311. doi: 10.1186/s13023-021-01922-1.
2
[Takayasu's arteritis--course, diagnosis and long term results of treatment].[高安动脉炎——病程、诊断及长期治疗结果]
Pol Arch Med Wewn. 1994 Jun;91(6):451-60.
3
[Large-vessel granulomatous vasculitis during the course of sarcoidosis: Takayasu's arteritis?].结节病病程中的大血管肉芽肿性血管炎:高安动脉炎?
Ann Dermatol Venereol. 2009 Dec;136(12):890-3. doi: 10.1016/j.annder.2009.03.021.
4
Two cases of Takayasu's arteritis occurring under anti-TNF therapy.两例发生在抗 TNF 治疗中的 Takayasu 动脉炎。
Joint Bone Spine. 2013 Mar;80(2):211-3. doi: 10.1016/j.jbspin.2012.07.015. Epub 2012 Sep 19.
5
Takayasu's arteritis. Protean manifestations.高安动脉炎。多种多样的表现。
J Adolesc Health Care. 1988 Sep;9(5):414-7. doi: 10.1016/0197-0070(88)90040-x.
6
Takayasu's arteritis with heart failure due to atherosclerosis.伴有动脉粥样硬化所致心力衰竭的高安动脉炎
Jpn J Med. 1990 May-Jun;29(3):309-12. doi: 10.2169/internalmedicine1962.29.309.
7
Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis.巨细胞动脉炎、颞动脉炎、风湿性多肌痛和高安动脉炎的免疫发病机制、诊断及治疗
Curr Opin Rheumatol. 1993 Jan;5(1):25-32. doi: 10.1097/00002281-199305010-00005.
8
[The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].[对诊断为合并肺血管受累的高安动脉炎的临床记录进行分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Aug;39(8):603-7. doi: 10.3760/cma.j.issn.1001-0939.2016.08.011.
9
Takayasu's disease and temporal arteritis.高安氏病和颞动脉炎。
Semin Vasc Surg. 1995 Dec;8(4):335-41.
10
[Branch retinal vein occlusion reveals Takayasu's arteritis].视网膜分支静脉阻塞揭示了高安动脉炎
J Fr Ophtalmol. 2004 Feb;27(2):162-5. doi: 10.1016/s0181-5512(04)96112-8.

引用本文的文献

1
Takayasu's Arteritis: A Special Case Report and Review of the Literature.Takayasu 动脉炎:1 例特殊病例报告并文献复习。
Medicina (Kaunas). 2024 Mar 9;60(3):456. doi: 10.3390/medicina60030456.
2
Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study.阿达木单抗与来氟米特治疗大动脉炎患者的疗效和安全性:一项回顾性队列研究。
RMD Open. 2024 Mar 4;10(1):e003992. doi: 10.1136/rmdopen-2023-003992.
3
[Not Available].[无可用内容]。
Tunis Med. 2023 May 5;101(5):502-506.
4
Coronary artery lesions in Takayasu arteritis.大动脉炎中的冠状动脉病变
Reumatologia. 2023;61(6):460-472. doi: 10.5114/reum/176483. Epub 2024 Jan 18.
5
Primary Systemic Vasculitides as a Cause of Group IV Pulmonary Hypertension.原发性系统性血管炎导致的 IV 型肺动脉高压。
Anatol J Cardiol. 2023 Dec 1;27(12):677-687. doi: 10.14744/AnatolJCardiol.2023.3650. Epub 2023 Nov 21.
6
The role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and monitoring of large vessel vasculitides - a review article.18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在大血管血管炎诊断和监测中的作用——一篇综述文章。
Am J Nucl Med Mol Imaging. 2023 Aug 15;13(4):127-135. eCollection 2023.
7
Clinical Characteristics and Outcomes of Aortic Arch Emergencies: Takayasu Disease, Fibromuscular Dysplasia, and Aortic Arch Pathologies: A Retrospective Study and Review of the Literature.主动脉弓急症的临床特征与预后:大动脉炎、纤维肌性发育异常及主动脉弓病变:一项回顾性研究及文献综述
Biomedicines. 2023 Aug 6;11(8):2207. doi: 10.3390/biomedicines11082207.
8
A pediatric case of Takayasu's arteritis with anti-neutrophil cytoplasmic antibody-associated vasculitis triggered by COVID-19 infection.一例由新冠病毒感染引发的合并抗中性粒细胞胞浆抗体相关性血管炎的小儿高安动脉炎病例。
North Clin Istanb. 2023 Jun 6;10(3):393-397. doi: 10.14744/nci.2022.01878. eCollection 2023.
9
18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice.18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在临床实践中用于大血管血管炎的诊断
Front Med (Lausanne). 2023 Jan 19;10:1103752. doi: 10.3389/fmed.2023.1103752. eCollection 2023.
10
Toe necrosis due to an arterial embolism revealing a Takayasu's arteritis.因动脉栓塞导致的足趾坏死,提示高安动脉炎。
BMJ Case Rep. 2023 Feb 3;16(2):e254203. doi: 10.1136/bcr-2022-254203.